Glycosylated Peptide Market Growth Drivers, Company Profiles, Technology Advancements, Global Industry Trends, Size, Share and Business Opportunities 2026
SEATTLE, March 25, 2021, (PHARMIWEB) — Global Glycosylated Peptide Market
Peptide drugs are potential therapeutic agents that are used against several diseases, owing to their features like high activity, target specificity, low toxicity, and minimal non-specific drug interactions. The low physicochemical properties such as poor membrane permeability and low target specific action when administered orally demands for improved peptide drug. Glycosylation of peptides is a promising strategy to modulate the physicochemical properties of peptide drugs and for penetration of peptides across biological membranes. Glycosylation of a peptide can be of two type N-linked glycosylation or O-linked glycosylation. Glycosylation of peptide drug enhances bioactivity, selectivity and prolong half-life of therapeutic drug. Advantages offered by glycosylated peptide over conventional peptide drug are the key factor driving growth of the glycosylated peptide market. For instance, Amgen’s Aranesp is used for treatment of anemia associated with chronic renal failure (CRF), having 5 N-linked oligosaccharide chain, which has three fold longer half-life as compared to Epogen, a 3 N-linked oligosaccharide chain. Furthermore, product approvals, inorganic strategies by key players, and various application of glycosylated peptide are some of the factors accelerating the growth of the global glycosylated peptide market.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1576
Global Glycosylated Peptide Market Analysis
New product launches by leading manufacturers are fostering the growth of the global glycosylated peptide market. For instance, in 2017, Pfizer Inc., received the U.S. Food and Drug Administration (FDA) approval for Ixifi (infliximab-qbtx), a chimeric human-murine monoclonal antibody, as a treatment for patients with rheumatoid arthritis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Furthermore, in February 2017, CT-P10 received approval from the European Commission and in June 2017, it was approved by the U.S. FDA.
Sumsung Bioepis’s Infliximab biosimilar candidate SB2 got the Ministry of Food and Drug Safety approval for Korea in 2016, European Commission approval for Europe in 2016, Therapeutic Goods Administration (TGA) approval for Australia in 2016, the U.S. FDA approval in 2017, and the Health Canada (HC) approval for Canada in 2017. Moreover, the company received European Commission (EC), Ministry of Food and Drug Safety (MFDS) and TGA approval for its Adalimumab biosimilar, SB5 in 2017 and 2018. However, challenges associated with the biosimilar product approval and stringent regulatory policies are restraining the growth of the global glycosylated peptide market.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Glycosylated Peptide Market Research Report: https://bit.ly/2PvsQLW
Increasing application of glycosylated peptide is expected to fuel growth of the glycosylated peptide market. For instance, in 2015, Sussex Research Laboratories Inc., a specialist in glycodesign and the synthesis of complex carbohydrates, announced successful clinical trials for Glycolastin, anti-aging glycopeptide cosmetic active. The in-vitro studies for comparing efficacy of Glycolastin against non-glycosylated peptide reported increased secretion of structural protein elastin, fibronectin, and collagens by fibroblast. Furthermore, company plans to commercialize Glycolastin, as a cosmetic active in topical anti-aging products.
Global Glycosylated Peptide Market – Regional Outlook
North America is expected to hold the leading position in the global glycosylated peptide market over the forecast period, owing to the increasing FDA approval of glycosylated peptide products in the region. Asia Pacific is expected to witness significant growth due to emerging market players and their market expansion strategies. For instance, in 2017, Amgen collaborated with Simcere Pharmaceutical Group for co-development and commercialization of its biosimilar products along with its four undisclosed pipeline biosimilar products for the treatment of inflammation and oncology in China.
Global Glycosylated Peptide Market – Key Competitors
The most prominent players operating in the global glycosylated peptide market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis, and Celltrion Inc.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/glycosylated-peptide-market-1576
These market players are deeply involved in adopting strategies, such as mergers and acquisitions, for expanding their geographical coverage and product portfolio. For instance, in 2014, Bachem AG, a peptide manufacturer and GlyTech Inc., a glycosylated drug developer, entered into co-promotional agreement for GlyTech’s glycosylation technology. The agreement leveraged Bachem by enhancing its sales and marketing resources and GlyTech to promote Bachem for manufacturing of its glycopeptides and glycoproteins.
Global Glycosylated Peptide Market Taxonomy
- Monoclonal Antibodies (mAbs)
- Erythropoietin (EPO)
- Other Products
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Table of Content
Global Glycosylated Peptide Market Research Report
Section 1: Global Glycosylated Peptide Industry Overview
Section 2: Global Economic Impact on Glycosylated Peptide Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Glycosylated Peptide Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Glycosylated Peptide Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire